LKFT Short Interest Unusually Active Before Today's Print

Lakefront Biotherapeutics enters its November 11 earnings report with short positioning moving more sharply than its own history would suggest, though the absolute level of bearish conviction remains modest by any measure.

Among its closest biotech peers, VKTX carries the heaviest short load, while CRVS gained more than 15% over the past week, the standout in the peer group. Lakefront's own short interest, at just under 4% of the lending pool, sits toward the lighter end of the peer set, though the weekly move in short positioning has been 2.2 standard deviations above the company's typical weekly change over the past year. That is an unusual jolt for a name that has not attracted sustained short conviction.

The borrow market tells a loose story. Availability runs at nearly 2,840%, meaning there are roughly 28 shares available to lend for every one already borrowed. That is well above the 52-week floor of 338%, and the cost to borrow has fallen around 19% over the past week to just under 2%. Neither figure suggests short sellers are scrambling for inventory or facing any pressure in the lending market.

The stock itself gained 2.6% over the past week, slightly trailing the peer median of 3.6% and giving back 1.3% in Monday's session to close at EUR 29.48. The 12% one-month gain provides context for where sellers may see risk around the print. A previous quarterly release in August triggered a 4.3% one-day gain; the most recent comparable, in May, produced a 2.4% one-day decline and a 3.4% five-day loss.

Ownership is heavily concentrated: Gilead Sciences holds 52% of shares, leaving a relatively thin public float for the short interest changes that are registering so visibly in percentage terms. The print will test whether the step-up in short positioning over the past week reflects genuine concern about the revenue trajectory, or simply thin-float mechanics amplifying otherwise ordinary repositioning.